Cipla Limited — Q4 FY26 earnings call

Call held 13 May 2026

Management summary

Cipla reported a strong Q4 FY26, with One India growing 15% Y-o-Y and full-year revenue reaching INR28,163 crores. North America achieved $780 million in annual revenue, securing key regulatory approvals and setting a target for $1 billion run rate by FY27 end. While full-year EBITDA margin was 21%, Q4 saw 15.2% due to investments and geopolitical factors. The company emphasized pipeline strength, strategic partnerships, and a commitment to AI-led transformation for future growth.

Highlights

  • One India business delivered robust performance, growing 15% Y-o-Y in Q4 and 9% Y-o-Y for the full year, surpassing INR12,500 crores in revenue.

  • North America achieved $780 million in annual revenue, with Albuterol market share increasing to 19.6% and regulatory approval for the first AB-rated generic Ventolin from a US facility.

  • EMEU operations scaled meaningfully, breaching the $400 million revenue mark despite geopolitical volatility.

  • Successful differentiated product launches across core therapies (Respiratory, Antimicrobial, Urology, Diabetes, Dermatology) and strategic partnerships (Eli Lilly, Mannkind, Pfizer, Inzpera Healthcare acquisition) enhanced portfolio.

  • All 3 US FDA inspections at Indian manufacturing facilities (Bommasandra, Sitec, Medispray) resulted in VAI or NAI classification, reflecting strong quality and compliance.

Concerns

  • Q4 EBITDA Margin was 15.2%, lower than the full year 21%, partly due to higher employee costs and geopolitical impact on operating expenses.

  • Lanreotide contribution is not factored into FY27 EBITDA margin guidance due to ongoing remediation efforts and supply disruption issues, with return expected only from FY28.

  • Geopolitical and war risks have caused some impact on sourcing costs in Q4 and potentially Q1 FY27, which are being closely monitored.

Key financials

2 periods

Q4

  • Revenue
    ₹6,541 Cr
  • EBITDA Margin
    15.2%
  • PAT
    ₹555 Cr
  • R&D Spend
    ₹509 Cr

FY26

  • Revenue
    ₹28,163 Cr
  • EBITDA Margin
    21%
  • PAT
    ₹3,879 Cr
  • R&D Spend
    ₹1,974 Cr

What they filed

Q1 FY27: revenue up 0.6%, net profit down 33.8% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue4,775 4,971 4,798 5,046 5,226 +9%4,498 −10%4,210 −12%5,078 +1%
EBITDA1,438 1,662 1,319 1,624 1,523 +6%721 −57%567 −57%1,086 −33%
Net profit1,178 1,438 1,485 1,303 1,211 +3%617 −57%385 −74%862 −34%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • One India
    15% Q4 Growth9% Full Year Growth₹12,500 Cr Full Year Revenue60% Chronic Mix
  • North America
    155 Mn Q4 Revenue780 Mn Annual Revenue19.6% Albuterol Market Share
  • One Africa
    14% Q4 Growth7% Full Year Growth (USD)
  • EMEU
    400 Mn Revenue

Capital allocation

high confidence
  • Debt Debt disclosed
    As of 31st March 2026, the debt on our balance sheet, including the lease liabilities stood at INR 614 crores with net cash equivalent balance at INR10,526 crores.
  • M&A Inzpera Healthcare Acquisition · Closed

    Enhanced portfolio on pediatric and wellness product side.

    Additionally, the acquisition of Inzpera Healthcare enhanced our portfolio on pediatric and wellness product side.
  • Liquidity Cash ₹10,526 Cr Net cash equivalent balance as of March 31, 2026, indicating a healthy net cash position.
    As of 31st March 2026, the debt on our balance sheet, including the lease liabilities stood at INR 614 crores with net cash equivalent balance at INR10,526 crores.

Guidance & targets

Revenue

  • North America Run Rate Revenue · end of FY27 · High confidence $1 billion
    In North America, we will concentrate on enhancing our commercial execution and accelerating new product introductions. And our aim is to cross $1 billion mark as a run rate towards the end of this financial year, i.e., FY '27.

    — Ashish Adukia

Profitability

  • EBITDA Margin Profitability · FY27 · High confidence 18.5% to 20%
    We expect the EBITDA margins to be in the range of 18.5% to 20% and this would be actually achieved with a sequential improvement quarter-on-quarter with the key improvement being in the second half of the year.

    — Ashish Adukia

  • FY28 Margins Profitability · FY28 · Medium confidence 20%+
    To be fair, I think it should 20 plus is something that we should anyway sustain going forward.

    — Ashish Adukia

R&D Spend

  • R&D Spend as % of Sales R&D Spend · FY27 · Medium confidence 7%
    I think that's very case specific. So it's difficult to call out an average number. We are guiding towards 7%-ish on R&D spend as a percentage of sales.

    — Achin Gupta

Product Pipeline

  • US Product Filings Product Pipeline · next 3 years · High confidence 40 to 50 products
    We remain very confident in our U.S. business outlook, which is supported by a pipeline of nearly 40 to 50 products to be filed over the next 3 years.

    — Achin Gupta

  • Respiratory Assets Commercialized Product Pipeline · FY27 · High confidence 4 assets
    In the Respiratory portfolio, 5 assets have been filed, including the generic Ventolin. 4 of these are expected to be commercialized in FY '27.

    — Achin Gupta

  • Peptides & Complex Generics Filings Product Pipeline · next 12 to 24 months · High confidence 3 more assets
    We aim to file 3 more Peptides & Complex Generics assets in the next 12 to 24 months.

    — Achin Gupta

What to watch in Q1 FY27

Lanreotide remediation progress and FDA reinspection

next quarter
Current Partner working on remediation, alternate US site identified
Target Closer visibility on exact remediation timelines and FDA reinspection outcome

Why it matters

Return of Lanreotide is a significant upside not factored into current guidance, impacting future revenue and margins.

So for Lanreotide, we have the partner who is working on the remediation efforts. And that's in full swing, and we are helping them as much as possible on navigating that part. So I think maybe by next quarter, we'll have closer visibility on their exact remediation time lines, which will also include a reinspection from the FDA.

Risks & concerns

  • Lanreotide supply disruption and remediation timeline uncertainty

    high

    Lanreotide contribution excluded from FY27 guidance due to ongoing remediation efforts and FDA reinspection, with return expected from FY28.

    Management acknowledged

  • Geopolitical and war risks impacting sourcing costs

    medium

    Geopolitical situation caused some impact on operating expenses in Q4 FY26 and potentially Q1 FY27, being closely monitored.

    Management acknowledged

Q&A highlights

6 direct
Impact of innovator's green Ventolin on Cipla's generic Ventolin launch Direct
The switching to another variant is -- I think that will be a process, which is not an automatic process under the U.S. law at this point of time. So we do not anticipate any near-term impact of that change as and when the transition starts to happen.

Addresses a potential competitive threat to a key new launch, with management indicating no immediate impact.

Asked by Vishal Manchanda

Delay in Advair approval due to Indore facility OAI Direct
I think your question is probably more historic. If you recall, we had OAI at our Indore facility. So we had to tech transfer to the U.S., which caused the delay. But now we are ready with everything. So it's just a matter of receiving the approval.

Clarifies the historical reason for a significant product's delay and confirms readiness for approval, indicating a potential near-term catalyst.

Asked by Vishal Manchanda

US revenue guidance of $1 billion exit run rate vs FY26 revenue, excluding Lanreotide Partial
Yes. So the guidance, I just wanted to clarify is a $1 billion run rate by the end of the year. We are not guiding for $1 billion revenue during the year, right? And the reason for that is because a lot of this is contingent on pipeline maturing.

Management clarifies the $1 billion is a run rate, not full-year revenue, and is contingent on pipeline maturity, managing analyst expectations for the ramp-up.

Asked by Surya Patra

Outlook and remediation efforts for Lanreotide Direct
So for Lanreotide, we have the partner who is working on the remediation efforts. And that's in full swing, and we are helping them as much as possible on navigating that part. So I think maybe by next quarter, we'll have closer visibility on their exact remediation time lines, which will also include a reinspection from the FDA.

Provides a timeline for visibility on a key product's return to market and outlines a two-pronged strategy, including an alternate manufacturing site.

Asked by Surya Patra

Impact of new Ventolin variant approval on market dynamics and pricing Direct
No. These are different products because they get substituted to the different innovator products. So it's a different NDC, different market. And we have CGT on the generic Ventolin. So we will actually be exclusive for a 6-month period. And we expect a significant uptick.

Explains the market differentiation and exclusivity period for the new Ventolin variant, suggesting a significant revenue opportunity without cannibalization.

Asked by Surya Patra

R&D spend of INR2,000 crores for FY26 vs. few ANDA filings, implying higher spend per ANDA Direct
Yes. Actually, we have gone up products, including some First-to-Files, which are on Oligonucleotide side as well. So we've gone into more respiratory, more peptide and more Oligo, which is resulting in higher spend per filing.

Justifies the higher R&D spend by highlighting a strategic shift towards more complex, high-value products like First-to-Files, Oligonucleotides, respiratory, and peptides.

Asked by Tushar Manudhane

India business growth sustainability and ability to outpace IPM growth Direct
Yes. So we are confident that we'll be able to deliver a strong double-digit growth as well as a market beating growth in FY '27, '28. And we've been seeing that consistent trend over the last couple of quarters.

Management expresses strong confidence in sustaining double-digit growth and outperforming the market in India, citing consistent recent trends.

Asked by Damayanti Kerai

Conservative EBITDA margin guidance (18.5-20%) despite strong US and India growth outlook Partial
See, I think we have made a lot of investment in the last 1 or 2 years, both on people as well as on R&D. And both these costs is going to sustain. People costs will continue to be high because we've made manufacturing facilities and to add the field force etcetera. I think more or less that investment phase is coming to an end.

Explains the margin outlook by pointing to sustained high costs from recent investments in people and R&D, suggesting a lag before revenue benefits fully materialize.

Asked by Vivek Agarwal

3 min read 6 chapters

Detailed narrative

Robust Performance in One India Business

Cipla's One India business demonstrated strong growth, achieving a 15% year-on-year increase in Q4 FY26 and a 9% year-on-year growth for the full fiscal year, with revenues surpassing INR12,500 crores. This performance was driven by double-digit growth across Branded Prescription, Trade Generics, and Consumer Health segments. Key chronic therapies like Respiratory, Anti-diabetes, Cardiac, and Urology delivered strong double-digit market growth, with the chronic mix reaching 60% as per IQVIA MAT March '26. The company also expanded its presence in the IPM by adding 4 brands exceeding INR100 crores, bringing the total to 33 such brands.

Strategic Advancements in North America and Global Expansion

The North America business reported an annual revenue of $780 million, with Q4 contributing $155 million. A significant milestone was the regulatory approval for the first AB-rated generic Ventolin with CGT from Cipla's US facility, with launch expected in the coming months. The company aims to achieve a $1 billion run rate in North America by the end of FY27, supported by a robust pipeline of 40-50 products to be filed over the next 3 years, including 12 first-to-files. Globally, the One Africa business grew 14% year-on-year in Q4, and EMEU operations scaled to over $400 million, showcasing diversified growth across geographies.

Pipeline Development and Strategic Partnerships

Cipla significantly enhanced its pipeline and portfolio through strategic initiatives. This included launching several differentiated products in core therapies and entering into collaborations with Eli Lilly for Yurpeak (obesity segment) and Mannkind Corporation for Afrezza India (rapid-acting inhaled insulin). The acquisition of Inzpera Healthcare further strengthened the pediatric and wellness product portfolio. The company is also focusing on complex generics, with 8 Peptides & Complex Generics assets already filed and 3 more planned for filing in the next 12-24 months, alongside investments in Oligonucleotide and two global biosimilar assets.

Financial Performance and Margin Outlook

For FY26, Cipla reported a total revenue of INR28,163 crores and an EBITDA margin of 21%. Q4 FY26 revenue stood at INR6,541 crores with an EBITDA margin of 15.2%. The lower Q4 margin was attributed to planned investments in talent and manufacturing readiness, as well as some impact from geopolitical situations on operating expenses. The company's R&D spend for FY26 was INR1,974 crores, representing approximately 7% of revenue, reflecting increased investment in complex products. Cipla expects FY27 EBITDA margins to be in the range of 18.5% to 20%, with sequential improvement anticipated in the second half of the year, excluding any contribution from Lanreotide.

Regulatory Compliance and AI Transformation

Cipla demonstrated strong regulatory compliance, with all three US FDA inspections at its Indian manufacturing facilities (Bommasandra, Sitec, and Medispray in Goa) resulting in VAI or NAI classifications during FY26. This achievement underscores the company's commitment to quality and operational excellence. Furthermore, Cipla is accelerating its AI-led transformation, aiming to become an AI-led pharma organization. This initiative focuses on broad-based implementation across functions like quality, regulatory, corporate, and R&D, with the goal of driving efficiency, productivity, and better decision-making.

Capital Structure and Future Growth Ambitions

As of March 31, 2026, Cipla maintained a healthy net cash equivalent balance of INR10,526 crores, with total debt (including lease liabilities) at INR614 crores. The company's ROIC for FY26 was 22.9%. Management highlighted a strategic focus on deploying capital towards accelerating the R&D pipeline, particularly in biosimilars, where they plan to build a pipeline of 6-8 in-house assets over the next 5-8 years. While open to limited in-licensing for near-term opportunities, the primary focus remains on differentiated specialty products for developed markets to ensure sustainable long-term growth.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls